{"id":350,"date":"2025-07-14T15:51:01","date_gmt":"2025-07-14T15:51:01","guid":{"rendered":"https:\/\/www.imagerie-medicale-95.fr\/pharmacie\/?p=350"},"modified":"2025-07-14T15:51:01","modified_gmt":"2025-07-14T15:51:01","slug":"abbvie-obtient-des-droits-exclusifs-pour-developper-et-commercialiser-un-nouvel-anticorps-trispecifique","status":"publish","type":"post","link":"https:\/\/www.imagerie-medicale-95.fr\/pharmacie\/abbvie-obtient-des-droits-exclusifs-pour-developper-et-commercialiser-un-nouvel-anticorps-trispecifique\/","title":{"rendered":"AbbVie obtient des droits exclusifs pour d\u00e9velopper et commercialiser un nouvel anticorps trispecifique"},"content":{"rendered":"

AbbVie a sign\u00e9 un accord de licence exclusif avec IGI Therapeutics, une filiale d’Ichnos Glenmark Innovation, pour d\u00e9velopper, fabriquer et commercialiser l’ISB 2001, un anticorps trispecifique ciblant l’antig\u00e8ne de maturation des cellules B (BCMA), CD38 et CD3, destin\u00e9 au traitement<\/a> des maladies oncologiques et auto-immunes. AbbVie obtiendra ces droits exclusifs dans plusieurs r\u00e9gions majeures, notamment l’Am\u00e9rique du Nord, l’Europe, le Japon et la Grande Chine. Sous r\u00e9serve de l’approbation r\u00e9glementaire, IGI recevra un paiement initial de 700 millions de dollars de la part d’AbbVie. De plus, IGI pourra recevoir jusqu’\u00e0 1,225 milliard de dollars en fonction des \u00e9tapes de d\u00e9veloppement et des objectifs r\u00e9glementaires et commerciaux, ainsi que des royalties \u00e0 deux chiffres bas\u00e9es sur les chiffres de vente nette. Roopal Thakkar, vice-pr\u00e9sident ex\u00e9cutif de la recherche et du d\u00e9veloppement et directeur scientifique d’AbbVie, a d\u00e9clar\u00e9 : “Les multispecifiques, y compris les anticorps trispecifiques, repr\u00e9sentent une nouvelle fronti\u00e8re en immuno-oncologie avec le potentiel de fournir des r\u00e9ponses plus profondes et plus durables en ciblant plusieurs cibles simultan\u00e9ment. Ce partenariat avec IGI refl\u00e8te notre engagement in\u00e9branlable \u00e0 faire progresser de nouvelles th\u00e9rapies pour les patients atteints de my\u00e9lome multiple, une maladie o\u00f9 des besoins non satisfaits importants subsistent malgr\u00e9 les progr\u00e8s r\u00e9cents.” L’ISB 2001, d\u00e9velopp\u00e9 \u00e0 l’aide de la plateforme prot\u00e9ique BEAT d’IGI, est un engageur de cellules T trispecifique con\u00e7u pour cibler BCMA et CD38 sur les cellules de my\u00e9lome et CD3 sur les cellules T. Il poss\u00e8de deux liants distincts qui ciblent les antig\u00e8nes associ\u00e9s au my\u00e9lome, am\u00e9liorant ainsi l’avidit\u00e9 m\u00eame \u00e0 de faibles niveaux d’expression et visant \u00e0 am\u00e9liorer la s\u00e9curit\u00e9 par rapport aux anticorps bispecifiques de premi\u00e8re g\u00e9n\u00e9ration. Cyril Konto, pr\u00e9sident et CEO d’IGI, a d\u00e9clar\u00e9 : “L’ISB 2001 illustre le potentiel de notre plateforme prot\u00e9ique BEAT \u00e0 g\u00e9n\u00e9rer des multispecifiques efficaces qui peuvent surmonter la r\u00e9sistance et am\u00e9liorer les r\u00e9sultats dans les cancers difficiles \u00e0 traiter. Notre partenariat avec AbbVie acc\u00e9l\u00e8re le chemin de l’ISB 2001 vers les patients et nous permet de nous concentrer sur le d\u00e9veloppement de la prochaine g\u00e9n\u00e9ration d’actifs BEAT en oncologie.” R\u00e9cemment, AbbVie a accept\u00e9 d’acqu\u00e9rir Capstan Therapeutics pour 2,1 milliards de dollars, renfor\u00e7ant ainsi son pipeline avec un candidat CAR-T au stade clinique in vivo.<\/p>\n","protected":false},"excerpt":{"rendered":"

AbbVie a sign\u00e9 un accord de licence exclusif avec IGI Therapeutics, une filiale d’Ichnos Glenmark Innovation, pour d\u00e9velopper, fabriquer et […]<\/p>\n","protected":false},"author":1,"featured_media":351,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[414],"tags":[],"class_list":["post-350","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-nouvelles"],"_links":{"self":[{"href":"https:\/\/www.imagerie-medicale-95.fr\/pharmacie\/wp-json\/wp\/v2\/posts\/350","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.imagerie-medicale-95.fr\/pharmacie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.imagerie-medicale-95.fr\/pharmacie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.imagerie-medicale-95.fr\/pharmacie\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.imagerie-medicale-95.fr\/pharmacie\/wp-json\/wp\/v2\/comments?post=350"}],"version-history":[{"count":1,"href":"https:\/\/www.imagerie-medicale-95.fr\/pharmacie\/wp-json\/wp\/v2\/posts\/350\/revisions"}],"predecessor-version":[{"id":356,"href":"https:\/\/www.imagerie-medicale-95.fr\/pharmacie\/wp-json\/wp\/v2\/posts\/350\/revisions\/356"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.imagerie-medicale-95.fr\/pharmacie\/wp-json\/wp\/v2\/media\/351"}],"wp:attachment":[{"href":"https:\/\/www.imagerie-medicale-95.fr\/pharmacie\/wp-json\/wp\/v2\/media?parent=350"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.imagerie-medicale-95.fr\/pharmacie\/wp-json\/wp\/v2\/categories?post=350"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.imagerie-medicale-95.fr\/pharmacie\/wp-json\/wp\/v2\/tags?post=350"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}